O Shaughnessy Asset Management LLC Acquires 228 Shares of United Therapeutics Co. (NASDAQ:UTHR)

O Shaughnessy Asset Management LLC increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% during the fourth quarter, HoldingsChannel.com reports. The fund owned 3,930 shares of the biotechnology company’s stock after buying an additional 228 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in United Therapeutics were worth $1,387,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the 4th quarter worth $25,000. Millstone Evans Group LLC purchased a new stake in United Therapeutics during the fourth quarter worth about $67,000. MassMutual Private Wealth & Trust FSB raised its position in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the period. Jones Financial Companies Lllp boosted its stake in United Therapeutics by 678.9% in the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 258 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of United Therapeutics during the 4th quarter valued at approximately $131,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $940,373.07. This represents a 79.51 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. This represents a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 72,500 shares of company stock valued at $26,134,500 in the last 90 days. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 4.8 %

Shares of NASDAQ:UTHR opened at $292.46 on Friday. United Therapeutics Co. has a 12 month low of $230.39 and a 12 month high of $417.82. The stock has a market cap of $13.13 billion, a P/E ratio of 12.84, a P/E/G ratio of 0.97 and a beta of 0.64. The company has a 50 day moving average of $333.78 and a 200 day moving average of $354.46.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the prior year, the firm posted $4.36 earnings per share. On average, equities analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of a number of research reports. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. UBS Group upped their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.